{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:51:08Z","timestamp":1782298268755,"version":"3.54.5"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C1011196"],"award-info":[{"award-number":["2021R1A2C1011196"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Overexpression of Twist1, one of the epithelial-mesenchymal transition-transcription factors (EMT-TFs), is associated with hepatocellular carcinoma (HCC) metastasis. Pelitinib is known to be an irreversible epidermal growth factor receptor tyrosine kinase inhibitor that is used in clinical trials for colorectal and lung cancers, but the role of pelitinib in cancer metastasis has not been studied. This study aimed to investigate the anti-migration and anti-invasion activities of pelitinib in HCC cell lines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using three HCC cell lines (Huh7, Hep3B, and SNU449 cells), the effects of pelitinib on cell cytotoxicity, invasion, and migration were determined by cell viability, wound healing, transwell invasion, and spheroid invasion assays. The activities of MMP-2 and -9 were examined through gelatin zymography. Through immunoblotting analyses, the expression levels of EMT-TFs (Snail1, Twist1, and ZEB1) and EMT-related signaling pathways such as mitogen-activated protein kinases (MAPKs) and Akt signaling pathways were measured. The activity and expression levels of target genes were analyzed by reporter assay, RT-PCR, quantitative RT-PCR, and immunoblotting analysis. Statistical analysis was performed using one-way ANOVA with Dunnett's Multiple comparison tests in Prism 3.0 to assess differences between experimental conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this study, pelitinib treatment significantly inhibited wound closure in various HCC cell lines, including Huh7, Hep3B, and SNU449. Additionally, pelitinib was found to inhibit multicellular cancer spheroid invasion and metalloprotease activities in Huh7 cells. Further investigation revealed that pelitinib treatment inhibited the migration and invasion of Huh7 cells by inducing Twist1 degradation through the inhibition of MAPK and Akt signaling pathways. We also confirmed that the inhibition of cell motility by Twist1 siRNA was similar to that observed in pelitinib-treated group. Furthermore, pelitinib treatment regulated the expression of target genes associated with EMT, as demonstrated by the upregulation of E-cadherin and downregulation of N-cadherin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on our novel finding of pelitinib from the perspective of EMT, pelitinib has the ability to inhibit EMT activity of HCC cells via inhibition of Twist1, and this may be the potential mechanism of pelitinib on the suppression of migration and invasion of HCC cells. Therefore, pelitinib could be developed as a potential anti-cancer drug for HCC.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-023-11217-2","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T03:26:09Z","timestamp":1690428369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Role of pelitinib in the regulation of migration and invasion of hepatocellular carcinoma cells via inhibition of Twist1"],"prefix":"10.1186","volume":"23","author":[{"given":"Sewoong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjeong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"1","key":"11217_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.17998\/jlc.2022.03.18","volume":"22","author":"SL Renne","year":"2022","unstructured":"Renne SL, Tommaso LD. A clinical and pathological update on hepatocellular carcinoma. J Liver Cancer. 2022;22(1):14\u201322.","journal-title":"J Liver Cancer"},{"issue":"1","key":"11217_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s43055-021-00612-z","volume":"52","author":"M Targe","year":"2021","unstructured":"Targe M, Yasam VR, Nagarkar R. Hepatocellular carcinoma with uncommon sites of metastasis: a rare case report. Egypt J Radiol Nucl Med. 2021;52(1):228.","journal-title":"Egypt J Radiol Nucl Med"},{"issue":"3","key":"11217_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/cells11030446","volume":"11","author":"S Kwon","year":"2022","unstructured":"Kwon S, Ban K, Hong YK, et al. PROX1, a Key Mediator of the Anti-Proliferative Effect of Rapamycin on Hepatocellular Carcinoma Cells. Cells. 2022;11(3):446.","journal-title":"Cells"},{"key":"11217_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2174\/2213988501812010009","volume":"12","author":"AK Singh","year":"2018","unstructured":"Singh AK, Kumar R, Pandey AK. Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers. Curr Chem Genom Transl Med. 2018;12:9\u201326.","journal-title":"Curr Chem Genom Transl Med"},{"issue":"1","key":"11217_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang A, Yang X-R, Chung W-Y, et al. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):146.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"11217_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4132\/KoreanJPathol.2013.47.1.9","volume":"47","author":"J Hyeon","year":"2013","unstructured":"Hyeon J, Ahn S, Park CK. CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection. Korean J Pathol. 2013;47(1):9\u201315.","journal-title":"Korean J Pathol"},{"issue":"9","key":"11217_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/onco.13819","volume":"26","author":"Saung MTPelosof LCasak S,","year":"2021","unstructured":"Saung MTPelosof LCasak S, et al. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. Oncologist. 2021;26(9):797\u2013806.","journal-title":"Oncologist"},{"issue":"3","key":"11217_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","volume":"7","author":"Kaseb AOHasanov ECao HST,","year":"2022","unstructured":"Kaseb AOHasanov ECao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):208\u201318.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"11217_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12906-021-03487-9","volume":"22","author":"T Yang","year":"2022","unstructured":"Yang T, Chen Y, Xu J, et al. Bioinformatics screening the novel and promising targets of curcumin in hepatocellular carcinoma chemotherapy and prognosis. BMC Complement Med Ther. 2022;22(1):21.","journal-title":"BMC Complement Med Ther"},{"key":"11217_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bmt.2022.10.002","volume":"1","author":"J Wang","year":"2023","unstructured":"Wang J, Xia S, Chen Y, et al. Screening and validation of prognostic indicator genes in the progression of HBV related hepatocellular carcinoma. Biomedical Technology. 2023;1:10\u20137.","journal-title":"Biomedical Technology"},{"issue":"4","key":"11217_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.21037\/tcr.2018.06.04","volume":"7","author":"Q Huang","year":"2018","unstructured":"Huang Q, Li J, Wei A. Identification of potential therapeutic targets in hepatocellular carcinoma using an integrated bioinformatics approach. Transl Cancer Res. 2018;7(4):849\u201358.","journal-title":"Transl Cancer Res"},{"key":"11217_CR12","first-page":"80","volume":"2","author":"Meier MANuciforo SCoto-Llerena M,","year":"2022","unstructured":"Meier MANuciforo SCoto-Llerena M, et al. Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report. Commun Med (Lond). 2022;2:80.","journal-title":"Commun Med (Lond)"},{"key":"11217_CR13","first-page":"7379","volume":"12","author":"C Xie","year":"2022","unstructured":"Xie C, Gu A, Khan M, et al. Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening. Front Oncol. 2022;12:7379.","journal-title":"Front Oncol"},{"issue":"8","key":"11217_CR14","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.3390\/curroncol29080434","volume":"29","author":"MY Feng","year":"2022","unstructured":"Feng MY, Chan LL, Chan SL. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Curr Oncol. 2022;29(8):5489\u2013507.","journal-title":"Curr Oncol"},{"issue":"1","key":"11217_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12(1):76.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"11217_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.devcel.2008.05.009","volume":"14","author":"J Yang","year":"2008","unstructured":"Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818\u201329.","journal-title":"Dev Cell"},{"issue":"4","key":"11217_CR17","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/s41418-019-0421-7","volume":"27","author":"Yuan KXie KLan T,","year":"2020","unstructured":"Yuan KXie KLan T, et al. TXNDC12 promotes EMT and metastasis of hepatocellular carcinoma cells via activation of \u03b2-catenin. Cell Death Differ. 2020;27(4):1355\u201368.","journal-title":"Cell Death Differ"},{"issue":"4","key":"11217_CR18","first-page":"5299","volume":"16","author":"Yu XZheng YZhu X,","year":"2018","unstructured":"Yu XZheng YZhu X, et al. Osteopontin promotes hepatocellular carcinoma progression via the PI3K\/AKT\/Twist signaling pathway. Oncol Lett. 2018;16(4):5299\u2013308.","journal-title":"Oncol Lett"},{"key":"11217_CR19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/1476-4598-13-236","volume":"13","author":"CH Hou","year":"2014","unstructured":"Hou CH, Lin FL, Hou SM, et al. Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1\/MEK\/ERK\/Elk-1\/TWIST-1 signaling pathway. Mol Cancer. 2014;13:236.","journal-title":"Mol Cancer"},{"issue":"2","key":"11217_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10911-010-9174-0","volume":"15","author":"A Bonnomet","year":"2010","unstructured":"Bonnomet A, Brysse A, Tachsidis A, et al. Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia. 2010;15(2):261\u201373.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"4","key":"11217_CR21","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/nar\/gkq890","volume":"39","author":"HL Franco","year":"2011","unstructured":"Franco HL, Casasnovas J, Rodr\u00edguez-Medina JR, et al. Redundant or separate entities?\u2013roles of Twist1 and Twist2 as molecular switches during gene transcription. Nucleic Acids Res. 2011;39(4):1177\u201386.","journal-title":"Nucleic Acids Res"},{"issue":"344","key":"11217_CR22","doi-asserted-by":"publisher","first-page":"re8","DOI":"10.1126\/scisignal.2005189","volume":"7","author":"DM Gonzalez","year":"2014","unstructured":"Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Science signaling. 2014;7(344):re8.","journal-title":"Science signaling."},{"issue":"2","key":"11217_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.21037\/tlcr.2016.04.07","volume":"5","author":"KR Jakobsen","year":"2016","unstructured":"Jakobsen KR, Demuth C, Sorensen BS, et al. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 2016;5(2):172.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"11217_CR24","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1158\/1078-0432.CCR-04-2550","volume":"11","author":"Mawrin CSasse TKirches E,","year":"2005","unstructured":"Mawrin CSasse TKirches E, et al. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res. 2005;11(11):4074\u201382.","journal-title":"Clin Cancer Res"},{"key":"11217_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/B978-0-12-381298-8.00027-7","volume":"484","author":"KH Paraiso","year":"2010","unstructured":"Paraiso KH, Van Der Kooi K, Messina JL, et al. Measurement of constitutive MAPK and PI3K\/AKT signaling activity in human cancer cell lines. Methods Enzymol. 2010;484:549\u201367.","journal-title":"Methods Enzymol"},{"issue":"12","key":"11217_CR26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.tibs.2013.10.001","volume":"38","author":"L Zhang","year":"2013","unstructured":"Zhang L, Zhou F, ten Dijke P. Signaling interplay between transforming growth factor-\u03b2 receptor and PI3K\/AKT pathways in cancer. Trends Biochem Sci. 2013;38(12):612\u201320.","journal-title":"Trends Biochem Sci"},{"issue":"38","key":"11217_CR27","doi-asserted-by":"publisher","first-page":"62767","DOI":"10.18632\/oncotarget.11232","volume":"7","author":"H Tang","year":"2016","unstructured":"Tang H, Massi D, Hemmings BA, et al. AKT-ions with a TWIST between EMT and MET. Oncotarget. 2016;7(38):62767\u201377.","journal-title":"Oncotarget"},{"issue":"1","key":"11217_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s42003-021-02958-6","volume":"5","author":"Sepporta MVPraz VBalmas Bourloud K,","year":"2022","unstructured":"Sepporta MVPraz VBalmas Bourloud K, et al. TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth. Commun Biol. 2022;5(1):42.","journal-title":"Commun Biol"},{"issue":"5","key":"11217_CR29","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/hep.23221","volume":"50","author":"MH Yang","year":"2009","unstructured":"Yang MH, Chen CL, Chau GY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology. 2009;50(5):1464\u201374.","journal-title":"Hepatology"},{"issue":"10","key":"11217_CR30","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/hmg\/ddaa076","volume":"29","author":"M Khot","year":"2020","unstructured":"Khot M, Sreekumar D, Jahagirdar S, et al. Twist1 induces chromosomal instability (CIN) in colorectal cancer cells. Hum Mol Genet. 2020;29(10):1673\u201388.","journal-title":"Hum Mol Genet"},{"issue":"48","key":"11217_CR31","doi-asserted-by":"publisher","first-page":"e23397","DOI":"10.1097\/MD.0000000000023397","volume":"99","author":"J Shen","year":"2020","unstructured":"Shen J, Chen Q, Li N, et al. TWIST1 expression and clinical significance in type I endometrial cancer and premalignant lesions: A retrospective clinical study. Medicine. 2020;99(48):e23397.","journal-title":"Medicine"},{"issue":"2","key":"11217_CR32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/hep.23311","volume":"51","author":"T Sun","year":"2010","unstructured":"Sun T, Zhao N, Zhao XL, et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology. 2010;51(2):545\u201356.","journal-title":"Hepatology"},{"key":"11217_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.omto.2020.05.016","volume":"18","author":"Xie BLiu YZhao Z,","year":"2020","unstructured":"Xie BLiu YZhao Z, et al. MYB Proto-oncogene-like 1-TWIST1 Axis Promotes Growth and Metastasis of Hepatocellular Carcinoma Cells. Mol Ther Oncolytics. 2020;18:58\u201369.","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"11217_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.21037\/tcr.2019.11.56","volume":"9","author":"P-W Zhao","year":"2020","unstructured":"Zhao P-W, Zhang J-W, Liu Y, et al. SRC-1 and Twist1 are prognostic indicators of liver cancer and are associated with cell viability, invasion, migration and epithelial-mesenchymal transformation of hepatocellular carcinoma cells. Transl Cancer Res. 2020;9(2):603.","journal-title":"Transl Cancer Res"},{"issue":"16","key":"11217_CR35","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1111\/bph.13189","volume":"172","author":"KK To","year":"2015","unstructured":"To KK, Poon DC, Wei Y, et al. Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer. Br J Pharmacol. 2015;172(16):4089\u2013106.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"11217_CR36","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1038\/s41598-022-06621-w","volume":"12","author":"AR Lee","year":"2022","unstructured":"Lee AR, Lee S, Shin JY, et al. Biomarker LEPRE1 induces pelitinib-specific drug responsiveness by regulating ABCG2 expression and tumor transition states in human leukemia and lung cancer. Sci Rep. 2022;12(1):2928.","journal-title":"Sci Rep"},{"issue":"12","key":"11217_CR37","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3346\/jkms.2011.26.12.1563","volume":"26","author":"H Kim","year":"2011","unstructured":"Kim H, Lim HY. Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. J Korean Med Sci. 2011;26(12):1563\u20138.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"11217_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0014-4827(02)00098-8","volume":"284","author":"RN Jorissen","year":"2003","unstructured":"Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284(1):31\u201353.","journal-title":"Exp Cell Res"},{"issue":"5","key":"11217_CR39","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.hoc.2004.06.002","volume":"18","author":"LM Ellis","year":"2004","unstructured":"Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am. 2004;18(5):1007\u201321.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"11217_CR40","first-page":"128","volume":"1866","author":"PK Singh","year":"2016","unstructured":"Singh PK, Singh H, Silakari O. Kinases inhibitors in lung cancer: From benchside to bedside. BBA Rev Cancer. 2016;1866(1):128\u201340.","journal-title":"BBA Rev Cancer"},{"issue":"2","key":"11217_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/jfb5020043","volume":"5","author":"J L\u00f3pez-Garc\u00eda","year":"2014","unstructured":"L\u00f3pez-Garc\u00eda J, Lehock\u00fd M, Humpol\u00ed\u010dek P, et al. HaCaT Keratinocytes Response on Antimicrobial Atelocollagen Substrates: Extent of Cytotoxicity, Cell Viability and Proliferation. J Funct Biomater. 2014;5(2):43\u201357.","journal-title":"J Funct Biomater"},{"issue":"5","key":"11217_CR42","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1021\/jf904182y","volume":"58","author":"C-J Weng","year":"2010","unstructured":"Weng C-J, Wu C-F, Huang H-W, et al. Evaluation of anti-invasion effect of resveratrol and related methoxy analogues on human hepatocarcinoma cells. J Agric Food Chem. 2010;58(5):2886\u201394.","journal-title":"J Agric Food Chem"},{"key":"11217_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3389\/fonc.2020.00499","volume":"10","author":"I Georgakopoulos-Soares","year":"2020","unstructured":"Georgakopoulos-Soares I, Chartoumpekis DV, Kyriazopoulou V, et al. EMT factors and metabolic pathways in cancer. Front Oncol. 2020;10:499.","journal-title":"Front Oncol"},{"issue":"7","key":"11217_CR44","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.3390\/ijms22073591","volume":"22","author":"E Kang","year":"2021","unstructured":"Kang E, Seo J, Yoon H, et al. The post-translational regulation of epithelial\u2013mesenchymal transition-inducing transcription factors in cancer metastasis. Int J Mol Sci. 2021;22(7):3591.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11217_CR45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/cr.2011.144","volume":"22","author":"Q Qin","year":"2012","unstructured":"Qin Q, Xu Y, He T, et al. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res. 2012;22(1):90\u2013106.","journal-title":"Cell Res"},{"issue":"10","key":"11217_CR46","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/cells8101118","volume":"8","author":"C-Y Loh","year":"2019","unstructured":"Loh C-Y, Chai JY, Tang TF, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118.","journal-title":"Cells"},{"issue":"1","key":"11217_CR47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH, et al. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5(1):1\u201317.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"11217_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-015-0454-6","volume":"14","author":"H Chen","year":"2015","unstructured":"Chen H, Hu L, Luo Z, et al. A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression. Mol Cancer. 2015;14(1):1\u201314.","journal-title":"Mol Cancer"},{"issue":"2","key":"11217_CR49","doi-asserted-by":"publisher","first-page":"jcs259018","DOI":"10.1242\/jcs.259018","volume":"135","author":"Y Wu","year":"2022","unstructured":"Wu Y, Ma Z, Zhang Y, et al. Cyclophilin A regulates the apoptosis of A549 cells by stabilizing Twist1 protein. J Cell Sci. 2022;135(2):jcs259018.","journal-title":"J. Cell Sci."},{"issue":"6","key":"11217_CR50","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1242\/jcs.196790","volume":"130","author":"J Wang","year":"2017","unstructured":"Wang J, Nikhil K, Viccaro K, et al. The Aurora-A\u2013Twist1 axis promotes highly aggressive phenotypes in pancreatic carcinoma. J Cell Sci. 2017;130(6):1078\u201393.","journal-title":"J Cell Sci"},{"issue":"10","key":"11217_CR51","doi-asserted-by":"publisher","first-page":"e0186191","DOI":"10.1371\/journal.pone.0186191","volume":"12","author":"W Qiao","year":"2017","unstructured":"Qiao W, Jia Z, Liu H, et al. Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis. PLoS ONE. 2017;12(10):e0186191.","journal-title":"PLoS ONE"},{"issue":"24","key":"11217_CR52","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1038\/onc.2010.115","volume":"29","author":"A Vichalkovski","year":"2010","unstructured":"Vichalkovski A, Gresko E, Hess D, et al. PKB\/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene. 2010;29(24):3554\u201365.","journal-title":"Oncogene"},{"issue":"11","key":"11217_CR53","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1158\/0008-5472.CAN-10-2914","volume":"71","author":"J Hong","year":"2011","unstructured":"Hong J, Zhou J, Fu J, et al. Phosphorylation of Serine 68 of Twist1 by MAPKs Stabilizes Twist1 Protein and Promotes Breast Cancer Cell InvasivenessTwist1 Phosphorylation and Breast Cancer Invasiveness. Can Res. 2011;71(11):3980\u201390.","journal-title":"Can Res"},{"issue":"1","key":"11217_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.tcb.2013.11.002","volume":"24","author":"A Tomas","year":"2014","unstructured":"Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014;24(1):26\u201334.","journal-title":"Trends Cell Biol"},{"issue":"5","key":"11217_CR55","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3892\/ijo.2021.5270","volume":"59","author":"J He","year":"2021","unstructured":"He J, Huang Z, Han L, et al. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). Int J Oncol. 2021;59(5):90.","journal-title":"Int J Oncol"},{"issue":"3","key":"11217_CR56","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41434-019-0059-6","volume":"26","author":"S Urnauer","year":"2019","unstructured":"Urnauer S, Schmohl KA, Tutter M, et al. Dual-targeted NIS polyplexes\u2014a theranostic strategy toward tumors with heterogeneous receptor expression. Gene Ther. 2019;26(3):93\u2013108.","journal-title":"Gene Ther"},{"issue":"6","key":"11217_CR57","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.molcel.2016.08.009","volume":"63","author":"H-J Lee","year":"2016","unstructured":"Lee H-J, Li C-F, Ruan D, et al. The DNA damage transducer RNF8 facilitates cancer chemoresistance and progression through twist activation. Mol Cell. 2016;63(6):1021\u201333.","journal-title":"Mol Cell"},{"issue":"9","key":"11217_CR58","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3390\/cells11091515","volume":"11","author":"A Daks","year":"2022","unstructured":"Daks A, Fedorova O, Parfenyev S, et al. The Role of E3 Ligase Pirh2 in Disease. Cells. 2022;11(9):1515.","journal-title":"Cells"},{"issue":"19","key":"11217_CR59","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1002\/1873-3468.13882","volume":"594","author":"C Wei","year":"2020","unstructured":"Wei C, Zhao X, Wang L, et al. TRIP suppresses cell proliferation and invasion in choroidal melanoma via promoting the proteasomal degradation of Twist1. FEBS Lett. 2020;594(19):3170\u201381.","journal-title":"FEBS Lett"},{"issue":"6","key":"11217_CR60","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/jcm8060757","volume":"8","author":"J Baulida","year":"2019","unstructured":"Baulida J, D\u00edaz VM, Herreros AG. Snail1: A Transcriptional Factor Controlled at Multiple Levels. J Clin Med. 2019;8(6):757.","journal-title":"J Clin Med"},{"issue":"16","key":"11217_CR61","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1158\/0008-5472.CAN-19-0049","volume":"79","author":"Ryu KJPark SMPark SH,","year":"2019","unstructured":"Ryu KJPark SMPark SH, et al. p38 Stabilizes Snail by Suppressing DYRK2-Mediated Phosphorylation That Is Required for GSK3\u03b2-\u03b2TrCP-Induced Snail Degradation. Can Res. 2019;79(16):4135\u201348.","journal-title":"Can Res"},{"issue":"18","key":"11217_CR62","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1158\/1078-0432.CCR-05-2722","volume":"12","author":"TK Lee","year":"2006","unstructured":"Lee TK, Poon RT, Yuen AP, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006;12(18):5369\u201376.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"11217_CR63","doi-asserted-by":"publisher","first-page":"e62171","DOI":"10.1371\/journal.pone.0062171","volume":"8","author":"L Hui","year":"2013","unstructured":"Hui L, Zhang S, Dong X, et al. Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS ONE. 2013;8(4):e62171.","journal-title":"PLoS ONE"},{"issue":"12","key":"11217_CR64","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.3390\/cancers13123027","volume":"13","author":"R Gonz\u00e1lez-Gonz\u00e1lez","year":"2021","unstructured":"Gonz\u00e1lez-Gonz\u00e1lez R, Ortiz-Sarabia G, Molina-Frechero N, et al. Epithelial-Mesenchymal Transition Associated with Head and Neck Squamous Cell Carcinomas: A Review. Cancers. 2021;13(12):3027.","journal-title":"Cancers"},{"key":"11217_CR65","doi-asserted-by":"publisher","first-page":"108846","DOI":"10.1016\/j.cbi.2019.108846","volume":"314","author":"H Agraval","year":"2019","unstructured":"Agraval H, Yadav UC. MMP-2 and MMP-9 mediate cigarette smoke extract-induced epithelial-mesenchymal transition in airway epithelial cells via EGFR\/Akt\/GSK3\u03b2\/\u03b2-catenin pathway: Amelioration by fisetin. Chem Biol Interact. 2019;314:108846.","journal-title":"Chem Biol Interact"},{"issue":"1","key":"11217_CR66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","volume":"278","author":"C Gialeli","year":"2011","unstructured":"Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278(1):16\u201327.","journal-title":"FEBS J"},{"key":"11217_CR67","doi-asserted-by":"publisher","first-page":"9423907","DOI":"10.1155\/2019\/9423907","volume":"2019","author":"C Scheau","year":"2019","unstructured":"Scheau C, Badarau IA, Costache R, et al. The role of matrix metalloproteinases in the epithelial-mesenchymal transition of hepatocellular carcinoma. Anal Cell Pathol. 2019;2019:9423907.","journal-title":"Anal Cell Pathol"},{"key":"11217_CR68","doi-asserted-by":"publisher","first-page":"119127","DOI":"10.1016\/j.gep.2020.119127","volume":"37","author":"SA Khales","year":"2020","unstructured":"Khales SA, Abbaszadegan MR, Majd A, et al. TWIST1 upregulates matrix metalloproteinase (MMP) genes family in esophageal squamous carcinoma cells. Gene Expr Patterns. 2020;37:119127.","journal-title":"Gene Expr Patterns"},{"key":"11217_CR69","doi-asserted-by":"publisher","first-page":"153473541988915","DOI":"10.1177\/1534735419889155","volume":"18","author":"MW Roomi","year":"2019","unstructured":"Roomi MW, Kalinovsky T, Bhanap B, et al. In Vitro Effect of Cytokines, Inducers, and Inhibitors on the Secretion of MMP-2 and MMP-9 in Hepatocarcinoma Cell Line SK-Hep-1. Integr Cancer Ther. 2019;18:1534735419889155.","journal-title":"Integr Cancer Ther"},{"key":"11217_CR70","doi-asserted-by":"publisher","first-page":"752725","DOI":"10.3389\/fonc.2021.752725","volume":"11","author":"L Mou","year":"2021","unstructured":"Mou L, Tian X, Zhou B, et al. Improving outcomes of tyrosine kinase inhibitors in hepatocellular carcinoma: new data and ongoing trials. Front Oncol. 2021;11:752725.","journal-title":"Front Oncol"},{"issue":"2","key":"11217_CR71","doi-asserted-by":"publisher","first-page":"204","DOI":"10.7150\/ijbs.22955","volume":"14","author":"Z Yang","year":"2018","unstructured":"Yang Z, Tam KYJIjobs. Combination strategies using EGFR-TKi in NSCLC therapy: learning from the gap between pre-clinical results and clinical outcomes. Int J Biol Sci. 2018;14(2):204.","journal-title":"Int J Biol Sci."},{"issue":"1","key":"11217_CR72","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13046-021-01968-w","volume":"40","author":"X-Y Luo","year":"2021","unstructured":"Luo X-Y, Wu K-M, He X-XJJoE, et al. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res. 2021;40(1):172.","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11217-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-11217-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11217-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T03:31:54Z","timestamp":1729827114000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11217-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["11217"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-11217-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"703"}}